Multi-drug-resistant Enterococcus faecium bacteraemia in a liver transplant recipient.

JMM case reports Pub Date : 2018-12-20 eCollection Date: 2019-01-01 DOI:10.1099/jmmcr.0.005172
Nathan A Summers, John Gharbin, Rachel Friedman-Moraco, G Marshall Lyon, Joseph Lutgring
{"title":"Multi-drug-resistant <i>Enterococcus faecium</i> bacteraemia in a liver transplant recipient.","authors":"Nathan A Summers,&nbsp;John Gharbin,&nbsp;Rachel Friedman-Moraco,&nbsp;G Marshall Lyon,&nbsp;Joseph Lutgring","doi":"10.1099/jmmcr.0.005172","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>Enterococcus faecium</i> is a commensal organism commonly colonizing the human gastrointestinal tract. Although it is generally a non-virulent organism, <i>E. faecium</i> can cause significant morbidity and mortality due to its inherent and acquired resistances to commonly used antimicrobials. Patients who are immunosuppressed are particularly vulnerable.</p><p><strong>Case presentation: </strong>A 65-75-year-old patient with a history of an orthotopic liver transplant for hepatitis C infection and diabetes was re-admitted to the hospital with abdominal pain and fever. The patient had several recent admissions related to the presentation reported here, which included treatment with a prolonged course of broad-spectrum antibiotics. The patient was found to have a recurrent liver abscess and blood cultures grew vancomycin-resistant <i>E. faecium</i>, non-susceptible to all tested agents: ampicillin, penicillin, vancomycin, daptomycin and linezolid. The patient was started initially on chloramphenicol intravenously while awaiting additional susceptibility testing, which ultimately revealed chloramphenicol non-susceptibility. Tigecycline was started but the patient ultimately decided to pursue hospice care.</p><p><strong>Conclusion: </strong>Multi-drug-resistant organisms are increasingly being recognized and are associated with poorer outcomes, particularly in immunosuppressed patients. We describe a particularly resistant organism and discuss potential therapeutic options.</p>","PeriodicalId":73559,"journal":{"name":"JMM case reports","volume":"6 1","pages":"e005172"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412035/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMM case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1099/jmmcr.0.005172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Introduction: Enterococcus faecium is a commensal organism commonly colonizing the human gastrointestinal tract. Although it is generally a non-virulent organism, E. faecium can cause significant morbidity and mortality due to its inherent and acquired resistances to commonly used antimicrobials. Patients who are immunosuppressed are particularly vulnerable.

Case presentation: A 65-75-year-old patient with a history of an orthotopic liver transplant for hepatitis C infection and diabetes was re-admitted to the hospital with abdominal pain and fever. The patient had several recent admissions related to the presentation reported here, which included treatment with a prolonged course of broad-spectrum antibiotics. The patient was found to have a recurrent liver abscess and blood cultures grew vancomycin-resistant E. faecium, non-susceptible to all tested agents: ampicillin, penicillin, vancomycin, daptomycin and linezolid. The patient was started initially on chloramphenicol intravenously while awaiting additional susceptibility testing, which ultimately revealed chloramphenicol non-susceptibility. Tigecycline was started but the patient ultimately decided to pursue hospice care.

Conclusion: Multi-drug-resistant organisms are increasingly being recognized and are associated with poorer outcomes, particularly in immunosuppressed patients. We describe a particularly resistant organism and discuss potential therapeutic options.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肝移植受者的多重耐药屎肠球菌菌血症。
简介:粪肠球菌是一种常见于人类胃肠道的共生生物。虽然它通常是一种无毒性的生物,但由于其对常用抗菌素的固有和获得性耐药性,粪肠杆菌可引起显著的发病率和死亡率。免疫抑制的患者尤其脆弱。病例介绍:65-75岁,因丙型肝炎感染和糖尿病行原位肝移植史,因腹痛和发热再次入院。该患者最近有几次与本文报道的表现相关的入院,其中包括延长疗程的广谱抗生素治疗。患者发现肝脓肿复发,血培养有耐万古霉素粪肠杆菌,对氨苄西林、青霉素、万古霉素、达托霉素和利奈唑胺等所有试验药物均不敏感。患者最初开始静脉注射氯霉素,同时等待进一步的药敏试验,最终发现氯霉素不敏感。开始使用替加环素,但患者最终决定寻求临终关怀。结论:越来越多的人认识到多重耐药生物,并且与较差的预后相关,特别是在免疫抑制患者中。我们描述了一种特别耐药的有机体,并讨论了潜在的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Post-traumatic endophthalmitis caused by Nocardia nova. Methylobacterium infection of an arthritic knee. Multi-drug-resistant Enterococcus faecium bacteraemia in a liver transplant recipient. Vibrio cholerae O6 gastroenteritis in a patient with lupus nephritis - a report from coastal Karnataka, South India. Reactivation of latent Histoplasma and disseminated cytomegalovirus in a returning traveller with ulcerative colitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1